Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 2
1993 5
1994 1
1995 3
1996 4
1997 2
1998 5
1999 6
2000 2
2001 5
2002 4
2003 3
2004 3
2005 2
2006 1
2007 3
2009 2
2010 1
2013 1
2014 1
2016 2
2018 1
2023 1
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Second-generation antihistamines: a comparative review.
Slater JW, Zechnich AD, Haxby DG. Slater JW, et al. Drugs. 1999 Jan;57(1):31-47. doi: 10.2165/00003495-199957010-00004. Drugs. 1999. PMID: 9951950
This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetirizine, ebastine, fexofenadine, ketotifen, loratadine, mizolastine and terfenadine, for significant features that affect choice. ...Conditions that result in accumul …
This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetirizine, ebastine, fexofen …
Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial.
Decraecker L, De Looze D, Hirsch DP, De Schepper H, Arts J, Caenepeel P, Bredenoord AJ, Kolkman J, Bellens K, Van Beek K, Pia F, Peetermans W, Vanuytsel T, Denadai-Souza A, Belmans A, Boeckxstaens G. Decraecker L, et al. Gut. 2024 Feb 23;73(3):459-469. doi: 10.1136/gutjnl-2023-331634. Gut. 2024. PMID: 38191268 Clinical Trial.
RESULTS: 202 participants (32 11 years, 68% female) were randomly allocated to receive ebastine (n=101) or placebo (n=101). Treatment with ebastine resulted in significantly more responders (12%, 12/92) for GRS+API compared with placebo (4%, 4/87, p=0.047) while the …
RESULTS: 202 participants (32 11 years, 68% female) were randomly allocated to receive ebastine (n=101) or placebo (n=101). Treatment …
Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis.
Ratner P, Falqués M, Chuecos F, Esbrí R, Gispert J, Peris F, Luria X, Rosales MJ. Ratner P, et al. Int Arch Allergy Immunol. 2005 Dec;138(4):312-8. doi: 10.1159/000088869. Epub 2005 Oct 11. Int Arch Allergy Immunol. 2005. PMID: 16224195
BACKGROUND: Few randomized studies have compared the efficacy of ebastine and loratadine in the symptomatic treatment of seasonal allergic rhinitis (SAR). ...Statistically significant differences in the mean change from baseline were found when comparing ebastine an …
BACKGROUND: Few randomized studies have compared the efficacy of ebastine and loratadine in the symptomatic treatment of seasonal all …
Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults.
Gehanno P, Bremard-Oury C, Zeisser P. Gehanno P, et al. Ann Allergy Asthma Immunol. 1996 Jun;76(6):507-12. doi: 10.1016/S1081-1206(10)63269-3. Ann Allergy Asthma Immunol. 1996. PMID: 8673684 Clinical Trial.
OBJECTIVE: To compare the efficacy of daily treatment with ebastine, 10 mg, ebastine, 20 mg, or cetirizine, 10 mg, for relieving symptoms of seasonal allergic rhinitis in adults. ...Ebastine, 20 mg, may have advantages over ebastine, 10 mg, and cetiriz …
OBJECTIVE: To compare the efficacy of daily treatment with ebastine, 10 mg, ebastine, 20 mg, or cetirizine, 10 mg, for relievi …
Pharmacokinetics and pharmacodynamics of ebastine in children.
Simons FE, Watson WT, Simons KJ. Simons FE, et al. J Pediatr. 1993 Apr;122(4):641-6. doi: 10.1016/s0022-3476(05)83555-3. J Pediatr. 1993. PMID: 8096545 Clinical Trial.
Ebastine is a new piperidine-containing, relatively nonsedating second-generation H1-receptor antagonist. ...Ebastine was absorbed well; peak carebastine concentrations occurred approximately 3 hours after dosing. ...
Ebastine is a new piperidine-containing, relatively nonsedating second-generation H1-receptor antagonist. ...Ebastine was abso …
Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval.
Gillen MS, Miller B, Chaikin P, Morganroth J. Gillen MS, et al. Br J Clin Pharmacol. 2001 Aug;52(2):201-4. doi: 10.1046/j.0306-5251.2001.01345.x. Br J Clin Pharmacol. 2001. PMID: 11488779 Free PMC article. Clinical Trial.
AIMS: The objective of this study was to compare the effects of high doses of ebastine with terfenadine and placebo on QTc. METHODS: Thirty-two subjects were randomly assigned to four treatments (ebastine 60 mg x day(-1), ebastine 100 mg x day(-1), terfenadin …
AIMS: The objective of this study was to compare the effects of high doses of ebastine with terfenadine and placebo on QTc. METHODS: …
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. The Ebastine Study Group.
Ratner PH, Lim JC, Georges GC. Ratner PH, et al. J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1101-7. doi: 10.1067/mai.2000.105525. J Allergy Clin Immunol. 2000. PMID: 10856142 Clinical Trial.
BACKGROUND: Ebastine and loratadine are 2 nonsedating second-generation H(1) antihistamines with once-daily dosing. ...Ebastine 20 mg and 10 mg doses were both efficacious and well tolerated in the treatment of SAR....
BACKGROUND: Ebastine and loratadine are 2 nonsedating second-generation H(1) antihistamines with once-daily dosing. ...Ebastine …
Ebastine in perennial allergic rhinitis.
Picado Vallés C, Cadahia García A, Cisteró Bahima A, Cano Cantudo L, Sanz Amaro A, Zayas Sanza JM. Picado Vallés C, et al. Ann Allergy. 1991 Dec;67(6):615-8. Ann Allergy. 1991. PMID: 1684273 Clinical Trial.
Oral ebastine, 10 mg once daily for seven days, and placebo were compared as treatment for active perennial allergic rhinitis in 151 patients in a multicenter, randomized, double-blind trial. Ebastine treatment produced a significant reduction in the incidence and s …
Oral ebastine, 10 mg once daily for seven days, and placebo were compared as treatment for active perennial allergic rhinitis in 151 …
Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects.
Chaikin P, Gillen MS, Malik M, Pentikis H, Rhodes GR, Roberts DJ. Chaikin P, et al. Br J Clin Pharmacol. 2005 Mar;59(3):346-54. doi: 10.1111/j.1365-2125.2005.02348.x. Br J Clin Pharmacol. 2005. PMID: 15752381 Free PMC article. Clinical Trial.
RESULTS: No significant changes in QTc interval from baseline were observed after 5 days administration of ebastine, loratadine or placebo. Ketoconazole/placebo increased the mean QTc (95% CI) by 6.96 (3.31-10.62) ms in the ebastine study and by 7.52 (4.15-10.89) ms …
RESULTS: No significant changes in QTc interval from baseline were observed after 5 days administration of ebastine, loratadine or pl …
Comparative clinical studies with ebastine: efficacy and tolerability.
Luria X. Luria X. Drug Saf. 1999;21 Suppl 1:63-7; discussion 81-7. doi: 10.2165/00002018-199921001-00008. Drug Saf. 1999. PMID: 10597869 Clinical Trial.
Ebastine is a nonsedating and selective histamine H1 receptor antagonist without anticholinergic or sedative effects at therapeutic doses. ...Ebastine was well tolerated in these studies and had no effect on the QTc interval....
Ebastine is a nonsedating and selective histamine H1 receptor antagonist without anticholinergic or sedative effects at therapeutic d …
64 results